文献速递产科母胎医学

围受孕期孕酮使用与妊娠期高血压疾病:一项基于人群的队列研究

Periconceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population-Based Cohort Study.
PubMed 文献 · BJOG · 2026-11-05

结果显示孕酮使用与妊娠期高血压风险显著降低相关(aRR 0.60),但对子痫前期无显著影响(aRR 0.97)。结论认为此关联不太可能具有临床意义。

要点

  • 围受孕期孕酮使用与妊娠期高血压风险降低相关(aRR 0.60)。
  • 孕酮使用与子痫前期风险无显著关联(aRR 0.97)。
  • 该人群研究结论提示此关联可能无临床意义。

核心结论

  • 这些发现不太可能具有临床意义。

研究设计与样本

  • 基于澳大利亚维多利亚州2009-2020年全州妊娠和出生数据,链接医院和药物处方数据的基于人群的队列研究。
  • 纳入初产妇,排除分娩日期或药物分发日期缺失者,以及孕中晚期暴露于孕酮者。
  • 比较围受孕期(孕前6周至孕早期末)暴露于孕酮与未暴露者,使用逆概率加权回归调整控制混杂因素。

主要发现

  • 孕酮使用与任何新发妊娠期高血压疾病风险显著降低相关(aRR 0.81 [95%CI 0.67,0.98];aRD -1.72% [95%CI -3.21%,-0.24%])。
  • 孕酮使用与妊娠期高血压绝对风险降低1.69%相关(aRR 0.60 [95%CI 0.43,0.83];aRD -1.69% [95%CI -2.52%,-0.86%]),但对子痫前期无显著变化(aRR 0.97 [95%CI 0.75,1.25];aRD -0.13% [95%CI -1.49%,1.23%])。
  • 仅限辅助生殖技术受孕的妊娠中,结果相似:妊娠期高血压风险显著降低(aRR 0.80 [95%CI 0.67,0.95];aRD -1.02% [95%CI -1.73%,-0.30%]),子痫前期无显著变化(aRR 0.96 [95%CI 0.83,1.11];aRD -0.25% [95%CI -1.23%,0.72%])。

临床怎么用

  • 围受孕期孕酮使用可能与妊娠期高血压风险降低相关,但证据提示该关联的临床意义有限,不应据此改变临床实践。
  • 对于子痫前期高风险孕妇,孕酮使用未显示显著保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether periconceptual use of progesterone is associated with an altered risk of new-onset hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, or superimposed preeclampsia). DESIGN: Population-based cohort study using statewide pregnancy and birth data from Victoria, Australia, linked with hospital and medication prescribing data. SETTING: Victoria, Australia (2009-2020). POPULATION: Nulliparous women who gave birth between 2009 and 2020 in Victoria, Australia. Women with missing delivery dates, medicine dispensation dates, or who were exposed to progesterone in the second or third trimester were excluded. METHODS: We compared nulliparous women exposed to progesterone in the periconceptual period (6 weeks preconception until the end of the first trimester) with those not exposed to progesterone. Inverse probability-weighted regression adjustment was used to control for confounding factors and investigate the effect of progesterone on the risk of preeclampsia (including superimposed preeclampsia) and gestational hypertension. MAIN OUTCOME MEASURES: Development of preeclampsia or gestational hypertension. RESULTS: Among 386 475 pregnancies, 5657 (1.5%) women used progesterone in the periconceptual period. Progesterone use was associated with a statistically significant reduction in the risk of any new onset hypertensive disorders of pregnancy (adjusted risk ratio [aRR] 0.81 [95% confidence interval [CI] 0.67, 0.98]; adjusted risk difference [aRD] -1.72% [95% CI -3.21%, -0.24%]). Investigating type of hypertension, we found progesterone use was associated with a 1.69% absolute reduced risk of gestational hypertension (aRR 0.60 [95% CI 0.43, 0.83]; aRD -1.69% [95% CI -2.52%, -0.86%]) but no significant change was observed for preeclampsia (aRR 0.97 [95% CI 0.75, 1.25]; aRD -0.13% [95% CI -1.49%, 1.23%]). Restricting our analyses to pregnancies conceived via assisted reproductive technology only, we found similar results, with a statistically significant reduction in the risk of gestational hypertension (aRR 0.80 [95% CI 0.67, 0.95]; aRD -1.02% [95% CI -1.73%, -0.30%]) but not preeclampsia (aRR 0.96 [95% CI 0.83, 1.11]; aRD -0.25% [95% CI -1.23%, 0.72%]). CONCLUSIONS: Among 386 475 nulliparous women, we found periconceptual progesterone use to be associated with a statistically significant reduction in the risk of gestational hypertension, but not preeclampsia. However, these findings are unlikely to be clinically meaningful.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Atkinson JA, Hiscock RJ, Forsythe A, et al. Periconceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population-Based Cohort Study. BJOG. 2026. PMID: 42987862. doi:10.1111/1471-0528.70355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。